Baird upgraded Argenx (ARGX) to Outperform from Neutral with an unchanged price target of $680. The firm citers valuation for the upgrade after the stock pulled back late last week due to pricing concerns related to the Medicare redesign implement this year. While the lower average revenue per patient on Vyvgart was not fully priced into the market and will continue, the drug remains well positioned for long-term volume-driven revenue growth, the analyst tells investors in a research note. As such, Baird views the recent pullback as creating a more attractive entry opportunity.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se: Buy Rating Affirmed Amid Pricing Strategy Confidence and Promising Growth Prospects
- Argenx price target lowered to EUR 525 from EUR 575 at Deutsche Bank
- Argenx Reports Record Growth and Strategic Success
- Argenx price target lowered to EUR 700 from EUR 740 at JPMorgan
- Argenx selloff a buying opportunity, says TD Cowen
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue